首页> 美国卫生研究院文献>other >Synthesis of a Disulfonated Derivative of Cucurbit7uril and Investigations of its Ability to Solubilize Insoluble Drugs
【2h】

Synthesis of a Disulfonated Derivative of Cucurbit7uril and Investigations of its Ability to Solubilize Insoluble Drugs

机译:葫芦7尿嘧啶二磺化衍生物的合成及其对不溶性药物的溶解能力研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Cucurbit[7]uril (CB[7]) is currently being investigated as a solubilizing agent for insoluble drugs. We recently found that acyclic CB[n]-type receptors that bear sulfonate solubilizing groups are well suited for this application. Herein, we report cucurbit[7]uril derivative (>1) that bears two sulfonate groups on its convex face that we hypothesized would be a superior solubilizing excipient for insoluble drugs. Before using >1 for drug solubilization experiments we showed that >1 does not self-associate and that it retained its ability to bind to diammonium compounds as common guests for CB[7] sized cavities. X-ray crystallography shows that >1 maintains the key structural features of CB[7] with only minor ellipsoidal deformations at the equator and carbonyl portals of >1. Unfortunately, the aqueous solubility of >1 (20 mM) is slightly lower than CB[7] (20-30 mM) which limits its potential as a solubilizing excipient for insoluble drugs. We created phase solubility diagrams for the solubilization of three drugs (camptothecin, albendazole, cinnarizine) with two different containers (>1 and CB[7]). CB[7] and >1 exhibit comparable solubilization abilities (e.g. Ka and maximum solubility) toward camptothecin and albendazole but >1 is an inferior solubilizing agent for cinnarizine because of the low solubility exhibited by the >1•cinnarizine complex.
机译:目前正在研究葫芦[7]尿素(CB [7])作为不溶性药物的增溶剂。我们最近发现,带有磺酸盐可溶基团的无环CB [n]型受体非常适合此应用。在这里,我们报道了葫芦[7]尿嘧啶衍生物(> 1 ),该衍生物在其凸面上带有两个磺酸盐基团,我们认为这将是不溶性药物的一种优异的增溶赋形剂。在使用> 1 进行药物增溶实验之前,我们表明> 1 不会自缔合,并且保留了与二铵化合物结合的能力,这是CB [7]大小的常见客体空腔。 X射线晶体学分析表明,> 1 保持了CB [7]的关键结构特征,在> 1 的赤道和羰基入口处只有很小的椭圆形变形。不幸的是,> 1 (20 mM)的水溶性略低于CB [7](20-30 mM),这限制了其作为不溶性药物的增溶赋形剂的潜力。我们创建了具有两种不同容器(> 1 和CB [7])的三种药物(喜树碱,阿苯达唑,肉桂那利)的增溶相溶解度图。 CB [7]和> 1 对喜树碱和阿苯达唑显示出可比的增溶能力(例如,Ka和最大溶解度),但> 1 是对肉桂利嗪的劣等增溶剂,因为其溶解度低由> 1 •肉桂那嗪复合物制成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号